HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1925 Butylhydroxyanisole Apr 25 2024
E1740 Mepazine hydrochloride Apr 25 2024
E1806 AGI-24512 Apr 25 2024
E1798 HOIPIN-8 Apr 23 2024
E1699 SR10221 Apr 22 2024
S8546 Alrizomadlin Apr 21 2024
A2162 Anti-mouse/human VLA-4 (CD49d)-InVivo Anti-mouse/human VLA-4 (CD49d)-InVivo reacts with human and mouse VLA-4 α chain also known as CD49d and integrin alpha 4. VLA-4 is a 150 kDa glycoprotein belonging to the integrin family that is expressed by many cell types including T and B lymphocytes, monocytes, eosinophils, basophils, mast cells, thymocytes, NK cells, and dendritic cells. Apr 19 2024
E4585 N-Arachidonyldopamine N-Arachidonyldopamine is a potent agonist of cannabinoid receptor 1 (CB1), with a Ki of 250 nM in rat brain membranes, showing 40-fold selectivity for CB1 over CB2 receptors. It also triggers intracellular calcium mobilization in N18TG2 neuroblastoma cells. Apr 17 2024
E1728 STC-15 STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. Apr 16 2024
E1904 SKF-34288 hydrochloride SKF-34288 hydrochloride(3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride) is an orally active, specific inhibitor of phosphoenolpyruvate carboxykinase (PEPCK) with Ki values of 2-9 μM. SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits cell proliferation, induces myogenic differentiation in vitro. Apr 14 2024
E1036 BMS-986278 BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases. Apr 14 2024
S9716 H3B-8800 H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations. Apr 10 2024
E1597 RMC-6236 RMC-6236 (RAS-IN-2) is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential. RMC-6236 exhibits strong anticancer efficacy in RAS-addicted cell lines, especially those with mutations at codon 12 of KRAS. Apr 10 2024
E1880 OTUB2-IN-1 OTUB2-IN-1 is a specific inhibitor of OTUB2, decreases PD-L1 protein expression in tumor cells, leading to suppressed tumor growth through enhanced infiltration of cytotoxic T lymphocytes (CTLs) within the tumor microenvironment. Apr 10 2024
E1903 SLU-PP-332 SLU-PP-332 is an agonist of pan-Estrogen Receptor/ERR with EC50 values of 98nM, 230nM, and 430 nM for ERRα, ERRβ, and ERRγ, respectively with the highest potency for ERRα. SLUPP-332 amplifies mitochondrial function and cellular respiration in skeletal muscle cell lines and also offers opportunities for researching metabolic ailments and enhancing muscle functionality. Apr 10 2024
E1876 GTS-21 dihydrochloride GTS-21 dihydrochloride(DMXB-A; DMBX-anabaseine) is a selective agonist of alpha7 nicotinic acetylcholine receptor (α7-nAChR) and exhibits anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also an antagonist of α4β2 with a Ki value of 20 nM for humanα4β2 and 5-HT3A receptor with an IC50 value of 3.1 μM. Apr 10 2024
E1924 TI17 TI17 is an inhibitor of thyroid hormone receptor-interacting protein Trip13. TI17 efficiently suppresses the proliferation of multiple myeloma (MM) cells and triggers cell cycle arrest and apoptosis. Trip13, an AAA-ATPase involved in double-strand break (DSB) repair, is targeted by TI17, leading to impaired function and heightened DNA damage. Apr 10 2024
E1710 LY2780301 LY2780301 is a highly selective adenosine triphosphate (ATP)-competitive dual inhibitor of p70S6K and Akt. LY2780301 binds to Akt, inhibiting its activity, which consequently blocks the PI3K/Akt signaling pathway which leads to reduced cell proliferation and the initiation of apoptosis in tumor cells. Apr 08 2024
E1849 TL12-186 TL12-186 is a cereblon-dependent multi-kinase PROTAC degrader. TL12-186 also inhibits CDK2/cyclin A and CDK9/cyclin T1 with IC50 values of 73 nM and 55 nM, respectively. Apr 08 2024
S8267 RapaLink-1 RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers. Apr 06 2024